Investigation Launched by Pomerantz for Ultragenyx Pharmaceutical Investors Amidst Stock Decline

Pomerantz Law Firm Investigates Ultragenyx Pharmaceutical Inc.

Pomerantz LLP, a prominent law firm renowned for its expertise in corporate, securities, and antitrust class litigation, has initiated an investigation concerning Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). This inquiry is aimed at determining whether the company, along with certain officers and/or directors, has engaged in any acts of securities fraud or other illicit business practices affecting investors.

Ultragenyx, which focuses on innovative treatments for rare diseases, recently made headlines when it announced on July 9, 2025, that the Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in the treatment of osteogenesis imperfecta (OI), a rare genetic disorder, is advancing towards a final analysis. This news followed a review by the Data Monitoring Committee, which suggested the conclusive analysis would be ready towards the end of the year.

However, after this announcement, Ultragenyx's stock suffered a notable setback, plummeting by $10.41 per share or approximately 25.11%, to close at $31.04 on July 10, 2025. This drastic decline has raised concerns among shareholders, prompting the Pomerantz Firm to act on behalf of affected investors.

The implications of this investigation could be substantial, as the Pomerantz Law Firm has a distinguished history of addressing grievances related to securities fraud and corporate misconduct. Renowned for securing millions in damages for class action members, the firm is continuing the legacy established by its founder, Abraham L. Pomerantz, often referred to as the dean of the class action bar.

If you are an investor in Ultragenyx Pharmaceutical Inc. and have experienced losses, Pomerantz encourages you to reach out to Danielle Peyton at their New York office for a preliminary discussion about your legal options. The firm is dedicated to protecting the rights of victims of corporate negligence and ensuring accountability in the business community.

The implications of these developments are considerable, not only for Ultragenyx and its shareholders but also for the wider pharmaceutical industry, where trust and transparency are paramount. Investors remain vigilant as they await further updates from both Ultragenyx and the Pomerantz Law Firm.

For additional information on how to join the class action or for further inquiries, contact Pomerantz via their provided email or phone number.

Pomerantz Law Firm continues its fight against securities fraud and breaches of fiduciary duty, standing firm in their commitment to securing justice for their clients. As the investigation unfolds, stakeholders are advised to stay informed and proactive in addressing their concerns regarding the company's actions.

For further investor support and updates, check the Pomerantz website: www.pomerantzlaw.com.